| 摘要 |
An in vitro method of predicting whether a patient, having a neurodevelopmental, neurological or neuropsychiatric disorder, will derive a clinical benefit if treated with a glycine reuptake inhibitor (GRI), via determination of the protein concentration of one, two, three, four five or six members of the complement factor H family or a mixture or a combination thereof and comparison against a representative value, wherein a higher value of the protein concentration in the patient's sample against the representative value is indicative of a patient whom will derive clinical benefit from treatment with GRI. |
